Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label multicenter study of VPRIV in Chinese patients with type 1 Gaucher disease
CTR20222758Phase 3Completed
- Sponsor
- Takeda
- Start
- Oct 2022
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of velaglucerase alfa in Gaucher disease type 1 (GD1), sponsored by Takeda. Started Oct 2022; status: completed.
02
Drugs
velaglucerase alfa
03
Conditions
Gaucher disease type 1 (GD1)
Beyond the preview
Go deeper on CTR20222758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222758.